Advertisement

Search Results

Advertisement



Your search for ,New matches 16916 pages

Showing 13401 - 13450


SIDEBAR: Expect Questions From Your Patients 

Physicians and patients should engage in open discussion” about the complex issues of cancer screening, overdiagnosis, and overtreatment, according to a report from the chairs of a National Cancer Institute working group tasked with developing a strategy to improve the current approach to cancer...

issues in oncology

Tackling Overdiagnosis and Overtreatment, by Words and by Deeds  

The complexity of the pathologic condition called cancer,” according to a Viewpoint article in the Journal of the American Medical Association,1 “complicates the goal of early diagnosis.” Failure to recognize that cancers are heterogeneous, and that not all progress to metastases and death, can...

Prominent Surgeon and Teacher LaSalle D. Leffall, Jr, MD, Promotes Hard Work and Education to Overcome Boundaries 

Reminiscing about his 65 years in medicine, LaSalle Doheny Leffall, Jr, MD, FACS, cites three events in his early childhood that would ultimately lead him to his position today as the Charles R. Drew Professor of Surgery at Howard University College of Medicine in Washington, DC. First, he was...

Genitourinary Cancer Expert Walter M. Stadler, MD, Named Section Chief of Hematology/Oncology at the University of Chicago Medicine

Walter M. Stadler, MD, an authority on prostate, kidney, bladder, and testicular cancers, has been named Chief of the Section of Hematology/Oncology at the University of Chicago Medicine. This position became effective August 15, 2013. Dr. Stadler, the Fred C. Buffet Professor of Medicine and...

St. Jude Children's Research Hospital Recognizes Childhood Cancer Awareness Month

Childhood cancer remains the leading cause of death by disease among young Americans. September marks Childhood Cancer Awareness Month, a time to highlight efforts to reduce the disease’s toll on children. At St. Jude, the past year has brought advances in understanding and treating childhood...

Oncology Meetings

September Inflammation, Microbiota, and CancerSeptember 19-20 • Bethesda, MarylandFor more information: ncifrederick.cancer.gov/events/microbiota/agenda.asp Continuum Cancer Centers of New York Conference on Quality of Care in OncologySeptember 20 • New York, New YorkFor more information:...

issues in oncology

ASCO Launches New Site to Seek Feedback from Cancer Community on Clinical Practice Guidelines

ASCO has launched a new wiki site to engage the cancer community in its clinical practice guideline development process. The new site will provide oncologists, practitioners and patients with an opportunity to provide feedback or submit evidence on individual published guidelines and can be...

issues in oncology

The Trials and Tribulations of a Revolutionary Cancer Drug 

A modest brass plaque above a booth in the Eagle Pub in Cambridge, notes, “On this spot, on February 28, 1953, Francis Crick and James Watson declared the discovery of DNA with these words: ‘We have discoverewd the secret of life.’” Announcing a major scientific advance over a pint of ale is a far...

survivorship

Cancer: Survivors in Focus Photo Exhibit Honors Cancer Survivors 

In June, the David J. Sencer Centers for Disease Control and Prevention (CDC) Museum in Atlanta, Georgia, opened a new photo exhibit featuring the faces of people living through and beyond a cancer diagnosis. The exhibit: Cancer: Survivors in Focus, tells the stories of cancer survivors while...

issues in oncology

The Direction of Immunotherapy Over the Next Decade 

The use of immunotherapy to target malignant cells in a variety of cancers—especially the PD-1 inhibitors lambrolizumab and nivolumab in the treatment of metastatic melanoma and the anti–PD-L1 agent MPDL3280A in the treatment of melanoma and lung, kidney, colorectal, and gastric cancers—made...

Final Publication of IOM Report on Learning Health Systems Available 

The Institute of Medicine (IOM) has issued the final publication of its report, Best Care at Lower Cost: The Path to Continuously Learning Health Care in America. ASCO continues to support the IOM report’s core recommendations for establishing a “learning health system” in the United States and...

Conquering Cancer by Encouraging Diversity in the Field of Oncology 

As the Conquer Cancer Foundation Grants and Awards Program has grown over the last 30 years, so has its purpose. Not only does the Grants and Awards Program support young researchers, foster mentoring relationships, and improve the quality of cancer care around the world, it also works to increase...

ASCO Congratulates QOPI-Certified Practices

QCP™: Recognizing Excellence The QOPI® Certification Program (QCP™) recognizes medical oncology and hematology/oncology practices that are committed to delivering the highest quality of cancer care. QCP evaluates an individual practice’s performance in areas that affect patient care and safety. The ...

Robert S. Miller, MD, FACP, Appointed Editor-in-Chief of Cancer.Net

Robert S. Miller, MD, FACP, a medical oncologist and recognized authority in breast cancer, survivorship care, and consumer health informatics, has been appointed Editor-in-Chief of ASCO’s patient information website, Cancer.Net (www.cancer.net). He assumed this role at the 2013 ASCO Annual Meeting ...

issues in oncology

Lidia Schapira, MD: Bridging Communication Gaps Between Oncologists and Patients 

Communicating the intricacies of oncology care to vulnerable patients with cancer and their caregivers requires a firm grasp of the nuances of language. One of the oncology community’s true champions in the art of breaking down communication barriers is Lidia Schapira, MD, a medical oncologist at...

skin cancer

Cytokine-Induced Killer Cells Effective Against Autologous Metastatic Melanoma Including Cells With Stemness Features 

In a study reported in Clinical Cancer Research, Gammaitoni and colleagues investigated the tumor-killing activity of cytokine-induced killer cells against autologous metastatic melanoma and putative cancer stem cells. The investigators developed a preclinical autologous model using same...

head and neck cancer

Couple Pledges $10 Million Gift to MD Anderson’s Head and Neck Cancer Center

The University of Texas MD Anderson Cancer Center in Houston, Texas, recently announced that Charles and Daneen Stiefel, of Raleigh, North Carolina, have pledged $10 million to the Head and Neck Cancer Center at MD Anderson. In honor of their generosity, the institution will name the Charles and...

thyroid cancer

Sorafenib Granted Priority Review for Differentiated Thyroid Cancer 

Bayer HealthCare and Onyx Pharmaceuticals recently announced that the FDA has granted priority review designation to the supplemental new drug application of sorafenib (Nexavar) tablets for the treatment of locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer....

leukemia

No Benefit/Detriment of Donor Change in Second Stem Cell Transplant for Leukemia Relapse 

Minimal data are available on outcomes of second allogeneic hematopoietic stem cell transplantation from unrelated donors after a first transplant in patients with hematologic relapse of acute leukemia. In a study reported in Journal of Clinical Oncology, Maximilian Christopeit, MD, of University...

pain management

Undertreatment of Cancer Pain Remains a Persistent Problem in Oncology 

Data indicate that for more than 2 decades, cancer pain has been undertreated in the United States. The paradox of this stubborn clinical problem is that oncology has the ability to manage the great majority of cancer pain. To clarify this issue, The ASCO Post recently spoke with nationally...

skin cancer

What Is the Optimal Treatment of Advanced Melanoma?  

With exciting targeted and immunotherapeutic agents now part of the arsenal for metastatic melanoma, which drug should move to the head of the line? Mario Sznol, MD, Professor of Medicine at Yale University School of Medicine, New Haven, Connecticut, has been involved in key clinical trials of the...

thyroid cancer

High-Tech Imaging Contributes to Overdiagnosis, Overtreatment of Low-Risk Thyroid Cancers  

A study from the Mayo Clinic Center for the Science of Health Care Delivery finds that advances in imaging technologies, including ultrasound, computed tomography, and magnetic resonance imaging, are fueling an epidemic in the diagnosis and treatment of thyroid cancers that are unlikely to ever...

skin cancer

Three 'Game-Changers' in the Treatment of Melanoma 

There have been three “game-changers” in the treatment of melanoma, Mark R. Albertini, MD, Associate Professor of Medicine at the University of Wisconsin in Madison, contended at the Best of ASCO Chicago meeting. The first, he explained, was the recognition of different genetic driver...

issues in oncology

Paging Dr. Google: Practicing Oncology in the Era of Social Media and Telemedicine  

Over the past few decades, economic and political factors have reshaped oncology, especially in the community setting. To defray risk, we’ve seen a trend toward oncology practices partnering with hospitals or aggregating into larger networks. Moreover, the Internet and the advent of telemedicine...

breast cancer

Platinum Agents in Triple-Negative Breast Cancer: Encouraging New Data 

For the treatment of triple-negative breast cancer, there is renewed interest in investigating the role of platinum chemotherapy, according to Melinda L. Telli, MD, Assistant Professor of Medicine at Stanford University, Palo Alto. At the Best of ASCO meeting in Los Angeles, Dr. Telli reviewed the...

breast cancer

Platinum-Based Treatment of Triple-Negative Breast Cancer

The last issue of The ASCO Post reports encouraging results with platinum-based treatment of triple-negative breast cancer (September 15, 2013). We predicted these findings 4 years ago in a presentation at the 2009 Breast Symposium.1 We compared the activity of a series of agents (platinum, taxane, ...

'Doing Nothing' Is Not an Option

I applaud The ASCO Post for continuing to raise awareness about futile medical care at the close of life with the recent publication of a commentary by Dr. Chandrakanth Are (“A Great Privilege to Die Beneath an Open Sky,” The ASCO Post, September 15, 2013, page 1). I would suggest, however, that we ...

skin cancer

Sunscreen Use Infrequently Discussed With Patients  

Although the incidence of skin cancer in increasing, “the rate at which physicians are mentioning sunscreen at patient visits is quite low, even for patients with a history of skin cancer,” according to an analysis of data from more than 18.30 billion patient visits. “Sun-protection counseling...

Smoking App for Teens 

E-cigarettes are one of the many issues addressed in the Tobacco-Free Teens app developed at MD Anderson Cancer Center in Houston. “What we are trying to say to teens is that you might as well avoid trying any of the cigarettes, or small cigars, or nicotine delivery devices, such as e-cigarettes,”...

issues in oncology

What You Need to Know About E-Cigarettes 

“I’ve seen a lot of puzzled people,” Alexander V. Prokhorov, MD, PhD, said, referring to people who see others using electronic or e-cigarettes. That puzzlement can go beyond wondering why people are smoking in public places and whether they are breaking the law, or just being annoying, to...

skin cancer

How to Recognize and Manage Ipilimumab-Induced Dermatologic Adverse Events 

Ipilimumab (Yervoy) is a fully humanized immunoglobulin (Ig)G1 monoclonal antibody that binds to and inhibits cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4). It acts as a T-cell potentiator, leading to increases in T-cell activation and interleukin-2 secretion. Ipilimumab is U.S. Food and...

PCORI Board Approves $114 Million for Patient-Centered Outcomes Research

The Patient-Centered Outcomes Research Institute (PCORI) Board of Governors recently approved 71 awards, totaling more than $114 million over 3 years, to fund comparative clinical effectiveness research designed to answer questions most important to patients and those who care for them. The awards...

William E. Evans, MD, Director, St. Jude Children's Research Hospital, to Retire in July 2014

St. Jude Children’s Research Hospital recently announced that William E. Evans, MD, Director and CEO, has decided to retire from his executive post in July of 2014. Dr. Evans has been with the organization for more than 40 years and has served as CEO for the past 10 years. Indelible Mark on History ...

St. Jude Children's Hospital Appoints Larry Kun, MD, Clinical Director

St. Jude Children’s Research Hospital officials have named Larry Kun, MD, as Clinical Director and Executive Vice President. Dr. Kun will guide all aspects of clinical care and oversee clinical operations, clinical effectiveness practices and patient care quality programs for the 7,800 patients who ...

health-care policy

For 2 Decades, Nancy Davenport-Ennis Has Worked to Ensure Access to Health Care for All Patients Diagnosed With Life-Threatening Illness 

As a young girl, Nancy Davenport-Ennis remembers hearing her parents tell stories about families struggling to pay their health-care expenses following a diagnosis of a serious illness like cancer. But it wasn’t until 3 decades later when she was coping with her own diagnosis of breast cancer and...

Donatori di Musica Initiative Creates a Unique Environment for Oncology Patients 

“Surely again, to heal men’s wounds by music’s spell.” —Euripides, Medea (480-406 BC) Commonly defined as organized sound, music has a unique power to stir human emotions, moods, and impressions. The salutary effect of music on the sick has been reported since antiquity. Aristotle and Plato wrote...

Oncology Meetings

October International Clinical Trials Workshop October 17-18 • Santiago, Chile For more information: www.asco.org/ASCOv2/About+ASCO/International+Affairs/International+Clinical+Trials+Workshops 64th Annual Scientific Meeting of The Royal Australian and New Zealand College of RadiologistsOctober...

hematologic malignancies

Focus on the Wisconsin Association of Hematology & Oncology 

The Wisconsin Association of Hematology & Oncology (WAHO) is among the youngest of ASCO’s State Affiliates. Formerly known as the Wisconsin Association of Medical Oncologists, WAHO was officially formed just 2 years ago and is already having an impact on oncologists and patients with cancer...

American/International Psychosocial Oncology Societies Host Event to Support Science and Practice of Psychosocial Care for Patients With Cancer 

Recently the American Psychosocial Oncology Society (APOS) and the International Psycho-Oncology Society (IPOS) held a fundraising event, Cruise for a Cause: Improving Psychosocial and Supportive Cancer Care, to raise money to advance the science and practice of psychosocial care for patients with...

integrative oncology

Herb-Drug Interactions in Oncology  

Guest Editor Integrative Oncology is guest edited by Barrie R. Cassileth, MS, PhD, Chief of the Integrative Medicine Service and Laurance S. Rockefeller Chair in Integrative Medicine at Memorial Sloan-Kettering Cancer Center, New York. The Integrative Medicine Service at Memorial Sloan-Kettering...

palliative care

Advances in Medical Oncology Over the Next Decade 

The next 10 years are expected to usher in unprecedented advances in oncology, including molecularly driven diagnostic and therapeutic developments, whole genome sequencing that results in true precision-based medicine, survivorship care plans that address long-term quality of life concerns, and...

lymphoma

Cancer Does Not Discriminate 

Looking back, my son Max’s fall as he was running after another little boy while playing baseball was such a blessing. Although he landed on his right arm, the fall didn’t seem severe enough to cause him to cry out in such excruciating pain. But after several hours of icing the bruise failed to...

gynecologic cancers

Cisplatin Plus Radiation Therapy for Advanced Cervical Cancer Improves Disease-Free Survival vs Radiotherapy Alone

Adding the chemotherapy drug cisplatin to a treatment plan of radiation therapy and high–dose rate brachytherapy for patients with stage IIIB cervical cancer is beneficial, according to research presented recently at the American Society for Radiation Oncology’s 55th Annual Meeting.1 Study Details...

cns cancers

Protecting Hippocampus During Whole-Brain Radiation Substantially Reduces Rate of Cognitive Decline 

Protecting the stem cells that reside in and around the hippocampus substantially reduces the rate of cognitive decline in patients during whole-brain radiotherapy without a significant risk of recurrence in that area of the brain, a new study shows. Results of the phase II clinical trial of...

prostate cancer

ALSYMPCA Trial: Updated Analysis of Survival With Radium-223 Treatment in Metastatic Prostate Cancer 

In a trial (ALSYMPCA trial) reported in The New England Journal of Medicine, Chris Parker, MD, from Royal Marsden Hospital in Surrey, UK, and colleagues compared the alpha emitter radium-223 dichloride (Xofigo) with best standard of care in men with castration-resistant prostate cancer and bone...

global cancer care

View From a Cancer Ward in Botswana 

Julie Livingston, PhD, MPH, is a Professor of History at Rutgers University. She is also an African historian with interdisciplinary training in public health and anthropology. Among other issues, her work considers the challenges of delivering oncology services in southern Africa, where there is a ...

global cancer care

Aftermath of the AIDS Pandemic: Cancer Care in Botswana  

The Republic of Botswana is slightly smaller than the state of Texas and with a population of just over 2 million people it is one of the world’s most sparsely populated countries. Botswana was among Africa’s poorest countries at the time it gained independence from the United Kingdom in 1966....

breast cancer

FDA Approves Neoadjuvant Pertuzumab for Early-Stage Breast Cancer

On September 30, 2013, the FDA granted accelerated approval to pertuzumab (Perjeta) in combination with trastuzumab (Herceptin) and docetaxel for patients with early-stage breast cancer in the neoadjuvant setting. Pertuzumab is the first FDA-approved drug for the neoadjuvant treatment of breast...

kidney cancer

Progression-Free Survival With Pazopanib Not Inferior to Sunitinib Benefit in Metastatic Renal Cell Carcinoma  

Pazopanib (Votrient) and sunitinib (Sutent) have been shown to provide progression-free survival benefit compared with placebo or interferon in phase III trials in metastatic renal cell carcinoma. In a noninferiority trial reported in The New England Journal of Medicine by Robert J. Motzer, MD, of...

Discover ASCO's Advanced Cancer Care Planning Booklet for Patients and Families

ASCO’s popular Advanced Cancer Care Planning booklet was recently updated with a different look and new content. Designed to help patients, families, and caregivers find the information they need to guide them through an advanced cancer diagnosis, this booklet is the newest addition to the ASCO...

Advertisement

Advertisement




Advertisement